The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Myosteatosis on computed tomography as a predictor of therapeutic response to CDK4/6 inhibitors plus aromatase inhibitors in patients with advanced breast cancer.
 
Min Hwan Kim
Stock and Other Ownership Interests - AIMA company
Honoraria - AstraZeneca; Boryung Pharmaceuticals; Boryung Pharmaceuticals; Celltrion; Celltrion; Daiichi Sankyo; Eisai; MSD
Consulting or Advisory Role - Boryung Pharmaceuticals; Daiichi Sankyo; Eisai
Research Funding - AstraZeneca; Boryung Pharmaceuticals; Celltrion; Daewoong Pharmaceutical
 
Hyunwook Kim
No Relationships to Disclose
 
Seungjin Baek
No Relationships to Disclose
 
Sookyeong Han
No Relationships to Disclose
 
Gun Min Kim
No Relationships to Disclose
 
Joohyuk Sohn
Stock and Other Ownership Interests - Daiichi Sankyo (I)
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol Myerss guibb (Inst); Celcuity (Inst); Daiichi Sankyo (Inst); Dragonfly Therapeutics (Inst); Eikon (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Hanmi Pharm (Inst); HLB Life Science (Inst); ILDONG PHARMACEUTICAL (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Olema Oncology (Inst); Pfizer (Inst); Qurient (Inst); Roche (Inst); Samyang Holdings (Inst); Sanofi (Inst); Seagan (Inst); Sermonix Pharmaceuticals (Inst)
 
Yumie Rhee
No Relationships to Disclose
 
Namki Hong
No Relationships to Disclose